Clinical Trial: Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06979531) titled 'Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity' on May 13.

Brief Summary: This is a Phase 2b, multicenter, randomized, double-blinded, placebocontrolled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD). The primary objective is to evaluate the efficacy, safety, and tolerability of IMVT-1402 compared to placebo, as measured by the change from baseline of Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (cliniESSDAI) at We...